Characterization of estrogen receptor-low-positive breast cancer
ConclusionsPR status as a surrogate marker of functional ER signaling provides critical information in this regard. These findings suggest that while ER-low-positive tumors are themselves heterogeneous, they often respond to endocrine treatment. Analysis of molecular signatures and standardization of therapeutic strategies are important to understand the biology of ER-low-positive tumors and to enable optimal treatment in the pursuit of individualized medicine.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Biology | Breast Cancer | Cancer | Cancer & Oncology | Molecular Biology | Pathology | Study